161 related articles for article (PubMed ID: 9607356)
1. Prognostic value of CA 19-9 levels in patients with carcinoma of the pancreas treated with radiotherapy.
Katz A; Hanlon A; Lanciano R; Hoffman J; Coia L
Int J Radiat Oncol Biol Phys; 1998 May; 41(2):393-6. PubMed ID: 9607356
[TBL] [Abstract][Full Text] [Related]
2. Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels.
Abrams RA; Grochow LB; Chakravarthy A; Sohn TA; Zahurak ML; Haulk TL; Ord S; Hruban RH; Lillemoe KD; Pitt HA; Cameron JL; Yeo CJ
Int J Radiat Oncol Biol Phys; 1999 Jul; 44(5):1039-46. PubMed ID: 10421536
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of carbohydrate antigen 19-9 in pancreatic cancer treated with radiochemotherapy.
Micke O; Bruns F; Kurowski R; Horst E; deVries AF; Hausler JW; Willich N; Schäfer U
Int J Radiat Oncol Biol Phys; 2003 Sep; 57(1):90-7. PubMed ID: 12909220
[TBL] [Abstract][Full Text] [Related]
4. CA 19-9 as a predictor for response and survival in advanced pancreatic cancer patients treated with chemoradiotherapy.
Koom WS; Seong J; Kim YB; Pyun HO; Song SY
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1148-54. PubMed ID: 18760544
[TBL] [Abstract][Full Text] [Related]
5. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
6. Radiation dose ≥54 Gy and CA 19-9 response are associated with improved survival for unresectable, non-metastatic pancreatic cancer treated with chemoradiation.
Golden DW; Novak CJ; Minsky BD; Liauw SL
Radiat Oncol; 2012 Sep; 7():156. PubMed ID: 22974515
[TBL] [Abstract][Full Text] [Related]
7. Intraoperative radiotherapy for resected pancreatic cancer: a multi-institutional retrospective analysis of 210 patients.
Ogawa K; Karasawa K; Ito Y; Ogawa Y; Jingu K; Onishi H; Aoki S; Wada H; Kokubo M; Etoh H; Kazumoto T; Takayama M; Negoro Y; Nemoto K; Nishimura Y;
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):734-42. PubMed ID: 20207498
[TBL] [Abstract][Full Text] [Related]
8. Preoperative CA 19-9 level is an important prognostic factor in patients with pancreatic adenocarcinoma treated with surgical resection and adjuvant concurrent chemoradiotherapy.
Hallemeier CL; Botros M; Corsini MM; Haddock MG; Gunderson LL; Miller RC
Am J Clin Oncol; 2011 Dec; 34(6):567-72. PubMed ID: 21150564
[TBL] [Abstract][Full Text] [Related]
9. Preoperative versus postoperative chemoradiation for patients with resected pancreatic adenocarcinoma.
Pendurthi TK; Hoffman JP; Ross E; Johnson DE; Eisenberg BL
Am Surg; 1998 Jul; 64(7):686-92. PubMed ID: 9655283
[TBL] [Abstract][Full Text] [Related]
10. Chemoradiation of unresectable pancreatic carcinoma: impact of pretreatment hemoglobin level on patterns of failure.
Morganti AG; Forni F; Macchia G; Valentini V; Smaniotto D; Trodella L; Balducci M; Cellini N
Strahlenther Onkol; 2003 Feb; 179(2):87-92. PubMed ID: 12590318
[TBL] [Abstract][Full Text] [Related]
11. Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas.
Montgomery RC; Hoffman JP; Riley LB; Rogatko A; Ridge JA; Eisenberg BL
Ann Surg Oncol; 1997; 4(7):551-6. PubMed ID: 9367020
[TBL] [Abstract][Full Text] [Related]
12. High-dose intraoperative radiotherapy for unresectable pancreatic cancer.
Shibamoto Y; Manabe T; Ohshio G; Sasai K; Nishimura Y; Imamura M; Takahashi M; Abe M
Int J Radiat Oncol Biol Phys; 1996 Jan; 34(1):57-63. PubMed ID: 12118565
[TBL] [Abstract][Full Text] [Related]
13. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
[TBL] [Abstract][Full Text] [Related]
14. External and intraoperative radiotherapy for resectable and unresectable pancreatic cancer: analysis of survival rates and complications.
Nishimura Y; Hosotani R; Shibamoto Y; Kokubo M; Kanamori S; Sasai K; Hiraoka M; Ohshio G; Imamura M; Takahashi M; Abe M
Int J Radiat Oncol Biol Phys; 1997 Aug; 39(1):39-49. PubMed ID: 9300738
[TBL] [Abstract][Full Text] [Related]
15. Preoperative chemotherapy, radiotherapy, and surgical resection of locally advanced pancreatic cancer.
Wanebo HJ; Glicksman AS; Vezeridis MP; Clark J; Tibbetts L; Koness RJ; Levy A
Arch Surg; 2000 Jan; 135(1):81-7; discussion 88. PubMed ID: 10636353
[TBL] [Abstract][Full Text] [Related]
16. Long-term survival after resection of pancreatic cancer: a single-center retrospective analysis.
Yamamoto T; Yagi S; Kinoshita H; Sakamoto Y; Okada K; Uryuhara K; Morimoto T; Kaihara S; Hosotani R
World J Gastroenterol; 2015 Jan; 21(1):262-8. PubMed ID: 25574100
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors for actual long-term survival in the era of multidisciplinary treatment for pancreatic ductal adenocarcinoma.
Nakagawa K; Akahori T; Nishiwada S; Nagai M; Nakamura K; Tanaka T; Tamamoto T; Ohbayashi C; Hasegawa M; Kichikawa K; Ikeda N; Sho M
Langenbecks Arch Surg; 2018 Sep; 403(6):693-700. PubMed ID: 30218193
[TBL] [Abstract][Full Text] [Related]
18. Elevated preoperative levels of CA 19-9 and CA 125 predicts overall survival time in the pancreatic adenocarcinoma. Single institution series.
Hogendorf P; Skulimowski A; Durczyński A; Kumor A; Poznańska G; Poznańska A; Oleśna A; Rut J; Øvereng Juliebø S; Szmiel A; Strzelczyk J
Pol Przegl Chir; 2020 Apr; 92(3):32-38. PubMed ID: 32759395
[TBL] [Abstract][Full Text] [Related]
19. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial.
Hess V; Glimelius B; Grawe P; Dietrich D; Bodoky G; Ruhstaller T; Bajetta E; Saletti P; Figer A; Scheithauer W; Herrmann R
Lancet Oncol; 2008 Feb; 9(2):132-8. PubMed ID: 18249033
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of CA 19-9 level in resectable pancreatic adenocarcinoma.
Rudnicki J; Agrawal AK; Grzebieniak Z; Zukrowski P; Zyśko D; Jelen M; Kielan W; Sebastian M; Słonina J; Marek G; Duda-Barcik Ł
Folia Histochem Cytobiol; 2010 Jan; 48(2):249-61. PubMed ID: 20675282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
